H1N1 Infection - Pipeline Review - H1 2014





Published: March 2014 | Pages: 175 | Format: PDF

 Summary 

 Global Markets Direct’s, ‘H1N1 Infection - Pipeline Review, H1 2014’, provides an overview of the H1N1 Infection’s therapeutic pipeline. 

 This report provides comprehensive information on the therapeutic development for H1N1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H1N1 Infection and special features on late-stage and discontinued projects. 

 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. 

 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

 

  •  The report provides a snapshot of the global therapeutic landscape of H1N1 Infection 
  •  The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities  
  •  The report reviews key players involved in the therapeutics development for H1N1 Infection and enlists all their major and minor projects 
  •  The report summarizes all the dormant and discontinued pipeline projects  
  •  A review of the H1N1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
  •  Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
  •  A detailed assessment of monotherapy and combination therapy pipeline projects 
  •  Coverage of the H1N1 Infection pipeline on the basis of target, MoA, route of administration and molecule type 
  •  Latest news and deals relating related to pipeline products 

 

 Reasons to buy 

 

  •  Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies 
  •  Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
  •  Develop strategic initiatives by understanding the focus areas of leading companies 
  •  Identify and understand important and diverse types of therapeutics under development for H1N1 Infection 
  •  Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
  •  Devise corrective measures for pipeline projects by understanding H1N1 Infection pipeline depth and focus of Indication therapeutics 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

 

 Introduction 7 

 Global Markets Direct Report Coverage 7 

 H1N1 Infection Overview 8 

 Therapeutics Development 9 

 Pipeline Products for H1N1 Infection - Overview 9 

 Pipeline Products for H1N1 Infection - Comparative Analysis 10 

 H1N1 Infection - Therapeutics under Development by Companies 11 

 H1N1 Infection - Therapeutics under Investigation by Universities/Institutes 15 

 H1N1 Infection - Pipeline Products Glance 16 

 Clinical Stage Products 16 

 Early Stage Products 17 

 Unknown Stage Products 18 

 H1N1 Infection - Products under Development by Companies 19 

 H1N1 Infection - Products under Investigation by Universities/Institutes 22 

 H1N1 Infection - Companies Involved in Therapeutics Development 23 

 Johnson & Johnson 23 

 Autoimmune Technologies, LLC 24 

 Sanofi 25 

 Inovio Pharmaceuticals, Inc. 26 

 Takeda Pharmaceutical Company Limited 27 

 CEL-SCI Corporation 28 

 Sarepta Therapeutics, Inc. 29 

 OPKO Health, Inc. 30 

 Medicago Inc. 31 

 NanoViricides, Inc. 32 

 NovaBay Pharmaceuticals, Inc. 33 

 Medigen Biotechnology Corporation 34 

 XOMA Corporation 35 

 Cytos Biotechnology AG 36 

 Synairgen plc 37 

 BioAlliance Pharma SA 38 

 Antigen Express, Inc. 39 

 Colby Pharmaceutical Company 40 

 Marinomed Biotechnologie GmbH 41 

 PT Bio Farma 42 

 TechnoVax, Inc. 43 

 AlphaVax, Inc. 44 

 EpiVax, Inc. 45 

 Kineta, Inc. 46 

 Protein Sciences Corporation 47 

 VaxInnate Corporation 48 

 Etubics Corporation 49 

 iBio, Inc. 50 

 Sirnaomics, Inc. 51 

 Vaxart, Inc. 52 

 ImmuneRegen BioSciences, Inc. 53 

 Cilian AG 54 

 Revivicor, Inc. 55 

 Vivaldi Biosciences Inc. 56 

 Vaxine Pty Ltd 57 

 Beijing Minhai Biotechnology Co., Ltd 58 

 TaiMed Biologics Inc. 59 

 Sanofi Pasteur SA 60 

 H1N1 Infection - Therapeutics Assessment 61 

 Assessment by Monotherapy Products 61 

 Assessment by Combination Products 62 

 Assessment by Target 63 

 Assessment by Mechanism of Action 66 

 Assessment by Route of Administration 68 

 Assessment by Molecule Type 70 

 Assessment by Therapeutic Class 73 

 Drug Profiles 77 

 Pandemic Flu Vaccine - Drug Profile 77 

 H1N1 Vaccine - Drug Profile 78 

 H1N1 Pandemic Influenza Vaccine - Drug Profile 80 

 PanBlok - Drug Profile 81 

 radavirsen - Drug Profile 83 

 VAX-128 - Drug Profile 84 

 HAC1 Vaccine - Drug Profile 85 

 H1N1 Seasonal Influenza Vaccine - Drug Profile 86 

 H1N1 Flu treatment - Drug Profile 87 

 Influenza vaccine Qb-Flu - Drug Profile 88 

 INO-3510 - Drug Profile 89 

 INO-3401 - Drug Profile 91 

 AEA-35p - Drug Profile 93 

 INO-3605 - Drug Profile 94 

 INO-3609 - Drug Profile 96 

 Subunit Vaccine For H1N1 Infection - Drug Profile 98 

 H1N1 Syncon Universal Influenza Vaccine - Drug Profile 100 

 Universal Flu Vaccine - Drug Profile 101 

 H1N1 Pandemic Flu Vaccine - Drug Profile 102 

 Homspera - Drug Profile 103 

 Flu Vaccine - Drug Profile 105 

 NV-INF-2 - Drug Profile 106 

 Vaccine For Pandemic Influenza (H1 & H5) - Drug Profile 107 

 NVC-612 - Drug Profile 108 

 H1N1 Flu Vaccine - Drug Profile 109 

 interferon beta-1a - Drug Profile 110 

 STP-702 - Drug Profile 112 

 F-10 Antibody Program - Drug Profile 113 

 TVX-002 - Drug Profile 114 

 Influenza VLP Vaccine - Drug Profile 115 

 iota-carrageenan - Drug Profile 116 

 TMB-571 - Drug Profile 117 

 Flufirvitide-3 - Drug Profile 118 

 Trimeric Aichi HA Vaccine - Drug Profile 119 

 JVRS-100 + Universal Influenza Vaccine - Drug Profile 120 

 Influenza vaccine - Drug Profile 122 

 NV-INF-1 - Drug Profile 123 

 Innate Immune Agonists - Drug Profile 125 

 BA-032 - Drug Profile 126 

 CiFlu - Drug Profile 127 

 Human Antibody Based Vaccines - Drug Profile 129 

 Chimigen Influenza Vaccine - Drug Profile 131 

 Cold-Adapted Avian Influenza Virus Vaccine - Drug Profile 132 

 Pam2Cys - Drug Profile 133 

 Pam2Cys Vaccine - Drug Profile 134 

 H1N1 Genetic Vaccine - Drug Profile 135 

 C-05 - Drug Profile 136 

 Matriptase Inhibitors - Drug Profile 137 

 Universal Influenza Vaccine - Drug Profile 138 

 GREFLU/CAL - Drug Profile 139 

 H1N1 Vaccine - Drug Profile 140 

 H1N1 Infection - Recent Pipeline Updates 142 

 H1N1 Infection - Dormant Projects 160 

 H1N1 Infection - Product Development Milestones 161 

 Featured News & Press Releases 161 

 Appendix 170 

 Methodology 170 

 Coverage 170 

 Secondary Research 170 

 Primary Research 170 

 Expert Panel Validation 170 

 Contact Us 171 

 Disclaimer 171 

  

 List of Tables 

 Number of Products under Development for H1N1 Infection, H1 2014 13 

 Number of Products under Development for H1N1 Infection - Comparative Analysis, H1 2014 14 

 Number of Products under Development by Companies, H1 2014 16 

 Number of Products under Development by Companies, H1 2014 (Contd..1) 17 

 Number of Products under Development by Companies, H1 2014 (Contd..2) 18 

 Number of Products under Investigation by Universities/Institutes, H1 2014 19 

 Comparative Analysis by Clinical Stage Development, H1 2014 20 

 Comparative Analysis by Early Stage Development, H1 2014 21 

 Comparative Analysis by Unknown Stage Development, H1 2014 22 

 Products under Development by Companies, H1 2014 23 

 Products under Development by Companies, H1 2014 (Contd..1) 24 

 Products under Development by Companies, H1 2014 (Contd..2) 25 

 Products under Investigation by Universities/Institutes, H1 2014 26 

 H1N1 Infection - Pipeline by Johnson & Johnson, H1 2014 27 

 H1N1 Infection - Pipeline by Autoimmune Technologies, LLC, H1 2014 28 

 H1N1 Infection - Pipeline by Sanofi, H1 2014 29 

 H1N1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 30 

 H1N1 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 31 

 H1N1 Infection - Pipeline by CEL-SCI Corporation, H1 2014 32 

 H1N1 Infection - Pipeline by Sarepta Therapeutics, Inc., H1 2014 33 

 H1N1 Infection - Pipeline by OPKO Health, Inc., H1 2014 34 

 H1N1 Infection - Pipeline by Medicago Inc., H1 2014 35 

 H1N1 Infection - Pipeline by NanoViricides, Inc., H1 2014 36 

 H1N1 Infection - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2014 37 

 H1N1 Infection - Pipeline by Medigen Biotechnology Corporation, H1 2014 38 

 H1N1 Infection - Pipeline by XOMA Corporation, H1 2014 39 

 H1N1 Infection - Pipeline by Cytos Biotechnology AG, H1 2014 40 

 H1N1 Infection - Pipeline by Synairgen plc, H1 2014 41 

 H1N1 Infection - Pipeline by BioAlliance Pharma SA, H1 2014 42 

 H1N1 Infection - Pipeline by Antigen Express, Inc., H1 2014 43 

 H1N1 Infection - Pipeline by Colby Pharmaceutical Company, H1 2014 44 

 H1N1 Infection - Pipeline by Marinomed Biotechnologie GmbH, H1 2014 45 

 H1N1 Infection - Pipeline by PT Bio Farma, H1 2014 46 

 H1N1 Infection - Pipeline by TechnoVax, Inc., H1 2014 47 

 H1N1 Infection - Pipeline by AlphaVax, Inc., H1 2014 48 

 H1N1 Infection - Pipeline by EpiVax, Inc., H1 2014 49 

 H1N1 Infection - Pipeline by Kineta, Inc., H1 2014 50 

 H1N1 Infection - Pipeline by Protein Sciences Corporation, H1 2014 51 

 H1N1 Infection - Pipeline by VaxInnate Corporation, H1 2014 52 

 H1N1 Infection - Pipeline by Etubics Corporation, H1 2014 53 

 H1N1 Infection - Pipeline by iBio, Inc., H1 2014 54 

 H1N1 Infection - Pipeline by Sirnaomics, Inc., H1 2014 55 

 H1N1 Infection - Pipeline by Vaxart, Inc., H1 2014 56 

 H1N1 Infection - Pipeline by ImmuneRegen BioSciences, Inc., H1 2014 57 

 H1N1 Infection - Pipeline by Cilian AG, H1 2014 58 

 H1N1 Infection - Pipeline by Revivicor, Inc., H1 2014 59 

 H1N1 Infection - Pipeline Vivaldi Biosciences Inc., H1 2014 60 

 H1N1 Infection - Pipeline by Vaxine Pty Ltd, H1 2014 61 

 H1N1 Infection - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2014 62 

 H1N1 Infection - Pipeline by TaiMed Biologics Inc., H1 2014 63 

 H1N1 Infection - Pipeline by Sanofi Pasteur SA, H1 2014 64 

 Assessment by Monotherapy Products, H1 2014 65 

 Assessment by Combination Products, H1 2014 66 

 Number of Products by Stage and Target, H1 2014 69 

 Number of Products by Stage and Mechanism of Action, H1 2014 71 

 Number of Products by Stage and Route of Administration, H1 2014 73 

 Number of Products by Stage and Molecule Type, H1 2014 76 

 Number of Products by Stage and Therapeutic Class, H1 2014 79 

 H1N1 Infection Therapeutics - Recent Pipeline Updates, H1 2014 146 

 H1N1 Infection - Dormant Projects, H1 2014 164 

  

 List of Figures 

 Number of Products under Development for H1N1 Infection, H1 2014 13 

 Number of Products under Development for H1N1 Infection - Comparative Analysis, H1 2014 14 

 Number of Products under Development by Companies, H1 2014 15 

 Number of Products under Investigation by Universities/Institutes, H1 2014 19 

 Comparative Analysis by Clinical Stage Development, H1 2014 20 

 Comparative Analysis by Early Stage Products, H1 2014 21 

 Assessment by Monotherapy Products, H1 2014 65 

 Number of Products by Top 10 Target, H1 2014 67 

 Number of Products by Stage and Top 10 Target, H1 2014 68 

 Number of Products by Top 10 Mechanism of Action, H1 2014 70 

 Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 71 

 Number of Products by Top 10 Route of Administration, H1 2014 72 

 Number of Products by Stage and Top 10 Route of Administration, H1 2014 73 

 Number of Products by Top 10 Molecule Type, H1 2014 74 

 Number of Products by Stage and Top 10 Molecule Type, H1 2014 75 

 Number of Products by Top 10 Therapeutic Class, H1 2014 77 

 Number of Products by Stage and Top 10 Therapeutic Class, H1 2014 78